@article {1586165,
	title = {Advances in the Medical Management of Neurotrophic Keratitis},
	journal = {Semin Ophthalmol},
	volume = {36},
	number = {4},
	year = {2021},
	month = {2021 May 19},
	pages = {335-340},
	abstract = {Neurotrophic Keratitis (NK) is a degenerative disorder of the cornea characterized by decreased or absent sensory corneal innervation, corneal epitheliopathy and impaired healing.The clinical presentation of NK can range from persistent epithelial defects to corneal perforation and management is often both challenging and protracted. Historically, the management of NK has consisted of non-specific strategies to facilitate corneal epithelial healing such as lubrication, bandage contact lenses and tarsorrhaphy. Recent advances in the development of therapeutics for NK have provided new and efficacious targeted strategies for its management.In this article, we review recombinant human nerve growth factor (Cenegermin), currently approved for clinical use in the United States and Europe, as well as other promising therapeutic options that are in pre-clinical development such as thymosine β4, connexin43 inhibitors, and artificial extracellular matrix components.},
	issn = {1744-5205},
	doi = {10.1080/08820538.2021.1900282},
	author = {Dohlman, Thomas H and Singh, Rohan Bir and Dana, Reza}
}
